Increased internalization of complement inhibitor CD59 may contribute to endothelial inflammation in obstructive sleep apnea

Science Translational Medicine

Volumn 8, Issue 320, 2016, Pages

  Emin, Memet ^a   Wang, Gang ^a   Castagna, Francesco ^a   Rodriguez Lopez, Josanna ^a   Wahab, Romina ^a   Wang, Jing ^a   Adams, Tessa ^a,b   Wei, Ying ^a,c   Jelic, Sanja ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; PEPTIDE; CHOLESTEROL; COMPLEMENT MEMBRANE ATTACK COMPLEX; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE PROTEIN;

ADULT; ARTICLE; BIOACCUMULATION; CELL ACTIVATION; CELL DAMAGE; CELL MEMBRANE; CELL PROTECTION; CELL SURFACE; CELLULAR DISTRIBUTION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; INTERMITTENT HYPOXIA; INTERNALIZATION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PEPTIDE LIBRARY; PHAGE DISPLAY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; PROTEIN TARGETING; SLEEP DISORDERED BREATHING; VASCULAR ENDOTHELIUM; CASE CONTROL STUDY; CELL SURFACE DISPLAY; COMPLICATION; DRUG EFFECTS; ENDOCYTOSIS; HYPOXIA; METABOLISM; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTIGENS, CD59; BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; CELL SURFACE DISPLAY TECHNIQUES; CHOLESTEROL; COMPLEMENT MEMBRANE ATTACK COMPLEX; ENDOCYTOSIS; ENDOTHELIUM, VASCULAR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOXIA; INFLAMMATION; MEMBRANE PROTEINS; SLEEP APNEA, OBSTRUCTIVE;

EID: 84954551017     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad0634     Document Type: Article

References (49)

1. T. Young, M. Palta, J. Dempsey, J. Skatrud, S. Weber, S. Badr, The occurrence of sleepdisordered breathing among middle-aged adults. N. Engl. J. Med. 328, 1230-1235 (1993).
2. J. M. Marin, S. J. Carrizo, E. Vicente, A. G. N. Agusti, Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: An observational study. Lancet 365, 1046-1053 (2005).
3. J. M. Marin, A. Agusti, I. Villar, M. Forner, D. Nieto, S. J. Carrizo, F. Barbé, E. Vicente, Y. Wei, F. J. Nieto, S. Jelic, Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA 307, 2169-2176 (2012).
4. H. K. Yaggi, J. Concato, W. N. Kernan, J. H. Lichtman, L. M. Brass, V. Mohsenin, Obstructive sleep apnea as a risk factor for stroke and death. N. Engl. J. Med. 353, 2034-2041 (2005).
5. M. Arzt, R. Luigart, C. Schum, L. Lüthje, A. Stein, I. Koper, C. Hecker, R. Dumitrascu, R. Schulz, Sleep-disordered breathing in deep vein thrombosis and acute pulmonary embolism. Eur. Respir. J. 40, 919-924 (2012).
6. I. Arnulf, M. Merino-Andreu, A. Perrier, S. Birolleau, T. Similowski, J.-P. Derenne, Obstructive sleep apnea and venous thromboembolism. JAMA 287, 2655-2656 (2002).
7. N. S. Marshall, K. K. H. Wong, P. Y. Liu, S. R. J. Cullen, M. W. Knuiman, R. R. Grunstein, Sleep apnea as an independent risk factor for all-cause mortality: The Busselton Health Study. Sleep 31, 1079-1085 (2008).
8. M. I. Cybulsky, M. A. Gimbrone Jr., Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251, 788-791 (1991).
9. C. Arnaud, P. C. Beguin, S. Lantuejoul, J.-L. Pepin, C. Guillermet, G. Pelli, F. Burger, V. Buatois, C. Ribuot, J.-P. Baguet, F. Mach, P. Levy, M. Dematteis, The inflammatory preatherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition. Am. J. Respir. Crit. Care Med. 184, 724-731 (2011).
10. S. Jelic, D. J. Lederer, T. Adams, M. Padeletti, P. C. Colombo, P. H. Factor, T. H. Le Jemtel, Vascular inflammation in obesity and sleep apnea. Circulation 121, 1014-1021 (2010).
11. L. Dyugovskaya, P. Lavie, L. Lavie, Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am. J. Respir. Crit. Care Med. 165, 934-939 (2002).
12. P. N. Hopkins, Molecular biology of atherosclerosis. Physiol. Rev. 93, 1317-1542 (2013).
13. S. Yusuf, S. Hawken, S. Ounpuu, T. Dans, A. Avezum, F. Lanas, M. McQueen, A. Budaj, P. Pais, J. Varigos, L. Lisheng; INTERHEART Study Investigators, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364, 937-952 (2004).
14. S. Jelic, M. Padeletti, S. M. Kawut, C. Higgins, S. M. Canfield, D. Onat, P. C. Colombo, R. C. Basner, P. Factor, T. H. LeJemtel, Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 117, 2270-2278 (2008).
15. V. Savransky, J. Jun, J. Li, A. Nanayakkara, S. Fonti, A. B. Moser, K. E. Steele, M. A. Schweitzer, S. P. Patil, S. Bhanot, A. R. Schwartz, V. Y. Polotsky, Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. Circ. Res. 103, 1173-1180 (2008).
16. L. F. Drager, L. A. Bortolotto, A. C. Figueiredo, E. M. Krieger, G. F. Lorenzi, Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 176, 706-712 (2007).
17. S. Meri, B. P. Morgan, A. Davies, R. H. Daniels, M. G. Olavesen, H. Waldmann, P. J. Lachmann, Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71, 1-9 (1990).
18. J. J. Devlin, L. C. Panganiban, P. E. Devlin, Random peptide libraries: A source of specific protein binding molecules. Science 249, 404-406 (1990).
19. O. O. Glebov, N. A. Bright, B. J. Nichols, Flotillin-1 defines a clathrin-independent endocytic pathway in mammalian cells. Nat. Cell Biol. 8, 46-54 (2006).
20. M. Frick, N. A. Bright, K. Riento, A. Bray, C. Merrified, B. J. Nichols, Coassembly of flotillins induces formation of membrane microdomains, membrane curvature, and vesicle budding. Curr. Biol. 17, 1151-1156 (2007).
21. T. Aït-Slimane, R. Galmes, G. Trugnan, M. Maurice, Basolateral internalization of GPIanchored proteins occurs via a clathrin-independent flotillin-dependent pathway in polarized hepatic cells. Mol. Biol. Cell 20, 3792-3800 (2009).
22. K. S. Kilgore, E. Schmid, T. P. Shanley, C. M. Flory, V. Maheswari, N. L. Tramontini, H. Cohen, P. A. Ward, H. P. Friedl, J. S. Warren, Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am. J. Pathol. 150, 2019-2031 (1997).
23. C. D. Collard, A. Agah, W. Reenstra, J. Buras, G. L. Stahl, Endothelial nuclear factor-kB translocation and vascular cell adhesion molecule-1 induction by complement: Inhibition with anti-human C5 therapy or cGMP analogues. Arterioscler. Thromb. Vasc. Biol. 19, 2623-2629 (1999).
24. N. Naslavsky, R. Weigert, J. G. Donaldson, Characterization of a nonclathrin endocytic pathway: Membrane cargo and lipid requirements. Mol. Biol. Cell 15, 3542-3552 (2004).
25. S. Parathath, S. L.Mick, J. E. Feig, V. Joaquin, L. Grauer, D. M. Habiel, M. Gassmann, L. B. Gardner, E. A. Fisher, Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism. Circ. Res. 109, 1141-1152 (2011).
26. Y. Du, X. Teng, N. Wang, X. Zhang, J. Chen, P. Ding, Q. Qiao, Q. Wang, L. Zhang, C. Yang, Z. Yang, Y. Chu, X. Du, X. Zhou, W. Hu, NF-kB and enhancer-binding CREB protein scaffolded by CREB-binding protein (CBP)/p300 proteins regulate CD59 protein expression to protect cells from complement attack. J. Biol. Chem. 289, 2711-2724 (2014).
27. W. Cui, Y. Zhao, C. Shan, G. Kong, N. Hu, Y. Zhang, S. Zhang, W. Zhang, Y. Zhang, X. Zhang, L. Ye, HBXIP upregulates CD46, CD55 and CD59 through ERK1/2/NF-kB signaling to protect breast cancer cells from complement attack. FEBS Lett. 586, 766-771 (2012).
28. D. Gancz, M. Lusthaus, Z. Fishelson, A role for the NF-kB pathway in cell protection from complement-dependent cytotoxicity. J. Immunol. 189, 860-866 (2012).
29. G. An, T. Miwa, W.-L. Song, J. A. Lawson, D. J. Rader, Y. Zhang, W.-C. Song, CD59 but not DAF deficiency accelerates atherosclerosis in female ApoE knockout mice. Mol. Immunol. 46, 1702-1709 (2009).
30. S. Yun, V. W. Y. Leung, M. Botto, J. J. Boyle, D. O. Haskard, Brief report: Accelerated atherosclerosis in low-density lipoprotein receptor-deficient mice lacking the membrane-bound complement regulator CD59. Arterioscler. Thromb. Vasc. Biol. 28, 1714-1716 (2008).
31. G. Wu, W. Hu, A. Shahsafaei, W. Song, M. Dobarro, G. K. Sukhova, R. R. Bronson, G.-. Shi, R. P. Rother, J. A. Halperin, X. Qin, Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ. Res. 104, 550-558 (2009).
32. R. Mehra, F. Xu, D. C. Babineau, R. P. Tracy, N. S. Jenny, S. R. Patel, S. Redline, Sleepdisordered breathing and prothrombotic biomarkers: Cross-sectional results of the Cleveland Family Study. Am. J. Respir. Crit. Care Med. 182, 826-833 (2010).
33. M. Yamashina, E. Ueda, T. Kinoshita, T. Takami, A. Ojima, H. Ono, H. Tanaka, N. Kondo, T. Orii, N. Okada, H. Okada, K. Inoue, T. Kitani, Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 323, 1184-1189 (1990).
34. N. Motoyama, N. Okada, M. Yamashina, H. Okada, Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene. Eur. J. Immunol. 22, 2669-2673 (1992).
35. Y. Nevo, B. Ben-Zeev, A. Tabib, R. Straussberg, Y. Anikster, Z. Shorer, A. Fattal-Valevski, A. Ta-Shma, S. Aharoni, M. Rabie, S. Zenvirt, H. Goldshmidt, Y. Fellig, A. Shaag, D. Mevorach, O. Elpeleg, CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy. Blood 121, 129-135 (2013).
36. B. Höchsmann, C. Dohna-Schwake, H. A. Kyrieleis, U. Pannicke, H. Schrezenmeier, Targeted therapy with eculizumab for inherited CD59 deficiency. N. Engl. J. Med. 370, 90-92 (2014).
37. M. Anliker, I. von Zabern, B. Höchsmann, H. Kyrieleis, C. Dohna-Schwake, W. A. Flegel, H. Schrezenmeier, C. Weinstock, A new blood group antigen is defined by anti-CD59, detected in a CD59-deficient patient. Transfusion 54, 1817-1822 (2014).
38. S. Sabharanjak, P. Sharma, R. G. Parton, S. Mayor, GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Dev. Cell 2, 411-423 (2002).
39. D. Song, G. Fang, S.-Z. Mao, X. Ye, G. Liu, Y. Gong, S. F. Liu, Chronic intermittent hypoxia induces atherosclerosis by NF-kB-dependent mechanisms. Biochim. Biophys. Acta 1822, 1650-1659 (2012).
40. S. Lim, P. Barter, Antioxidant effects of statins in the management of cardiometabolic disorders. J. Atheroscler. Thromb. 21, 997-1010 (2014).
41. S. Mayor, S. Sabharanjak, F. R. Maxfield, Cholesterol-dependent retention of GPI-anchored proteins in endosomes. EMBO J. 17, 4626-4638 (1998).
42. A. R. Kinderlerer, R. Steinberg, M. Johns, S. K. Harten, E. A. Lidington, D. O. Haskard, P. H. Maxwell, J. C. Mason, Statin-induced expression of CD59 on vascular endothelium in hypoxia: A potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. Arthritis Res. Ther. 8, R130 (2006).
43. S. Ledoux, D. Laouari, M. Essig, I. Runembert, G. Trugnan, J. B. Michel, G. Friedlander, Lovastatin enhances ecto-5'-nucleotidase activity and cell surface expression in endothelial cells: Implication of rho-family GTPases. Circ. Res. 90, 420-427 (2002).
44. A. E. Silver, S. D. Beske, D. D. Christou, A. J. Donato, K. L. Moreau, I. Eskurza, P. E. Gates, D. R. Seals, Overweight and obese humans demonstrate increased vascular endothelial NAD(P)H oxidase-p47phox expression and evidence of endothelial oxidative stress. Circulation 115, 627-637 (2007).
45. C. Antoniades, C. Shirodaria, N. Warrick, S. Cai, J. de Bono, J. Lee, P. Leeson, S. Neubauer, C. Ratnatunga, R. Pillai, H. Refsum, K. M. Channon, 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 114, 1193-1201 (2006).
46. X. L. Aranguren, X. Agirre, M. Beerens, G. Coppiello, M. Uriz, I. Vandersmissen, M. Benkheil, J. Panadero, N. Aguado, A. Pascual-Montano, V. Segura, F. Prósper, A. Luttun, Unraveling a novel transcription factor code determining the human arterial-specific endothelial cell signature. Blood 122, 3982-3992 (2013).
47. M. W. Johns, A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep 14, 540-545 (1991).
48. G. Box, W. Hunter, J. S. Hunter, Statistics for Experimenters (John Wiley and Sons Inc., Hoboken, NJ, 2005).
49. J. Röhmel, Precision intervals for estimates of the difference in success rates for binary random variables based on the permutation principle. Biom. J. 38, 977-993 (1996).